Psychopharmacology of 5-HT(1A) receptors. by Cowen, P

Dopaminergic agents by Cowen, P

Increased prolactin responses to d-fenfluramine in obsessive-compulsive disorder - Author's reply by Cowen, P

Current antidepressant treatments: what do we have and what do we need? by Cowen, P

Augmentation strategies: 5-HT and beyond by Cowen, P

5-HT RECEPTOR SENSITIVITY DURING ANTIDEPRESSANT DRUG-TREATMENT by Cowen, P

Augmentation of SSRI treatment by Cowen, P

PSYCHOTROPIC-DRUGS AND HUMAN 5-HT NEUROENDOCRINOLOGY by Cowen, P

Biological markers in depression by Cowen, P

Recent views on the role of 5-hydroxytryptamine in depression by Cowen, P

Slow, repetitive transcranial magnetic stimulation was effective for major depression: Commentary by Cowen, P

Neuroendocrine and clinical responses in obsessive-compulsive disorder. by Cowen, P

MAKE-BELIEVE IN PSYCHIATRY OR THE PERILS OF PROGRESS - VANPRAAG,HM by Cowen, P

Prolactin response to tryptophan during mianserin treatment. by Cowen, P

Commentary on 'The management of treatment-resistant affective disorder: clinical perspectives'. by Cowen, P

Classification of depressive disorders. by Cowen, P

Has psychopharmacology got a future? by Cowen, P

Commentary on STAR*D: a summary and UK perspective. by Cowen, P

Depression resistant to tricyclic antidepressants. by Cowen, P

A big tent? by Cowen, P